Wegovy, Zepbound and similar medications all lead to metabolic improvements, but scientists are starting to unpick the ...

Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival ...

Anti-obesity medications (AOMs) such as GLP-1s will play an unquestionable long-term role in balancing the “food trilemma”.

A study has identified the key role of lateral septum neurons in the effects of the anti-obesity drug liraglutide, offering ...

The growth of highly sought-after weight-loss drugs like Wegovy and Ozempic, otherwise known as GLP-1 medications, represents ...

A research group led by Prof. Zhu Yingjie from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of ...

The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

Biden issued the statement in response to news that Eli Lilly will offer a direct-to-consumer version of its anti-obesity drug Zepbound for $399 for a month's supply, down from a typical list price of ...

is releasing a single-dose version of its weight loss drug Zepbound for patients who don't have insurance coverage. The ...

Current federal regulation restricts Medicare from covering drugs prescribed solely for weight loss. However, in March 2024, ...

A new study estimates that 3.6 million Medicare beneficiaries are most likely to become eligible for semaglutide. The study also estimates eligibility and associated maximum costs if different ...